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BACKGROUND: The identiﬁcation of polymorphisms associated with a disease can help to elucidate its pathogenesis,
and this knowledge can be used to improve prognosis for women with a particular disorder, such as polycystic ovary
syndrome (PCOS). Since an altered response to ovarian stimulation is also a characteristic of the disease, further
knowledge about its aetiology could help in deﬁning the parameters that determine the response of an individual to
ovarian stimulation. METHODS: PubMed and EMBASE databases were systematically searched for gene association
studies published until the end of August 2007, using search criteria relevant to PCOS and ovarian response to stimu-
lation. Data from additional papers identiﬁed through hand searches were also included; 139 publications were
reviewed. RESULTS: Several genes involved in ovarian function and metabolism are associated with increased sus-
ceptibility to PCOS, but none is strong enough to correlate alone with susceptibility to the disease, or response to
therapy. A single-nucleotide polymorphism in exon 10 of the FSH receptor (FSHR) gene, FSHR p.N680S, was consist-
ently identiﬁed as having a signiﬁcant association with ovarian response to FSH. CONCLUSIONS: No consistent
association between gene polymorphism and PCOS could be identiﬁed. The FSHR gene may play a signiﬁcant role
in the success of ovarian stimulation, and can be used as a marker to predict differences in FSHR function and
ovarian response to FSH. Genotyping the FSHR p.N680S polymorphism may provide a means of identifying a
population of poor responders before in vitro fertilization procedures are initiated.
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Introduction
Genetic studies contribute towards our understanding of disease
pathogenesis and hold the promise of improving our ability to indi-
vidualize treatment for patients. In this review, we ﬁrst explain the
rationale and methodology of studies that identify gene–disease
associations. We then review the extensive body of research
aimed at identifying contributing genetic factors in polycystic
ovary syndrome (PCOS) and assess genetic studies that have
investigated patients’ ovarian response to gonadotrophin treatment
using assisted reproductive techniques. This provides the ﬁrst sys-
tematically selected summary of published studies about all genes
that have so far been investigated in these areas. We then discuss
the limitations of such studies and provide recommendations for
using this information in the future, with the aim of guiding the
design and interpretation of future studies.
Genetic association studies
Genetic association studies are used to investigate genes or genetic
markers that might be associated with a particular disease pheno-
type or trait. These studies rely on the identiﬁcation and character-
ization of natural variants or polymorphisms in the DNA sequence
among individuals. If an association is present, a particular variant
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Advance Access publication July 4, 2008will be seen more often than expected by chance in an individual
carrying the trait. Variants fall into several categories, depending
on where they occur relative to a gene. First, variants can occur
within or outside a gene. Those that occur within a gene may
occur within an exon, an intron or regulatory regions. Regulatory
regions control gene transcription and include the promoter region
upstream of the gene and the 30-untranslated region downstream of
the protein-coding region (Fig. 1). Variants within a gene can be
functional or silent. Functional variation within a gene can be
the direct cause of a phenotype abnormality or may increase sus-
ceptibility to a disease. Functional variants in coding regions can
change the protein sequence; in non-coding regions they may
have effects on RNA transcription and processing (Kim et al.,
2005; Wang et al., 2005). Silent variants occur in protein-coding
DNA but do not change the sequence of a gene product. In the
majority of cases, variation that occurs outside a gene is used as
a tag to identify nearby functional variation within a gene
(Fig. 2). Such analyses are based on a chromosomal property
called linkage disequilibrium. Linkage disequilibrium refers to
the observation that in the general population, two DNA variants
that are located close to each other tend to be observed together
more frequently than two variants that are located further apart.
Variants may be single-base changes, known as single-nucleotide
polymorphisms (SNPs), or they may occur as insertions or
deletions of one base or more.
Until recently, the high cost of testing for genetic variation has
meant that most analyses have concentrated on the study of a
limited number of functional genetic variants, primarily SNPs,
in speciﬁc genes. Candidate genes for genotyping are selected
according to their function: they encode proteins that are
thought to have a role in the disease or response to treatment. Var-
iants within the candidate genes are most often selected because
they occur within exons and would result in a change in amino
acid sequence in the protein. Alternatively, they are located in
non-coding regions, but change a transcription factor-binding
site or inﬂuence splicing efﬁciency, affecting the expression of a
protein. The main advantage of the candidate SNP approach is
that such studies are affordable, as only a limited number of var-
iants are studied and a relatively small sample size can be used.
In the context of genome-wide analyses, the main advantages of
using SNPs are their abundance in the genome, and the possibility
of conducting genotyping in a high-throughput manner. To date, a
wealth of results has been obtained from studies addressing the
problem of potential associations between genetic polymorphisms
and PCOS or ovarian response to gonadotrophins.
Materials and Methods
We systematically searched the PubMed and EMBASE databases for
gene association studies published until the end of August 2007, using
the terms ‘PCOS’, ‘polycystic and (ovary or ovaries)’, ‘ovarian and
response’, ‘OHSS’ or ‘ovarian and hyperstimulation’, combined
with ‘polymorphism or polymorphisms’ or ‘mutation or mutations’.
The search was not limited by language of publication. Two authors
(B.C.J.M.F. and M.S.) then selected relevant studies using the
Figure 1: Graphic representation of types of genetic variants, showing insertion/deletion (ins/del) polymorphisms, both coding and non-coding SNPs, and repeat
polymorphisms such as tandem repeats or VNTR.
Variants are shown occurring within a gene (in this example the INS gene), but can also occur outside of genes. Other types of genetic variations that affect larger
regions, such as copy number variations, are not shown. SNP, single-nucleotide polymorphism; VNTR, variable number of tandem repeats.
Figure 2: Principles of genetic association, and possible explanations for an
observed association.
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460following criteria: more than one patient, inclusion of a control group
and with at least the abstract written in English. Also included were
additional papers identiﬁed through hand searches carried out by the
same authors.
All results of selected studies are comprehensively summarized in
functional group-speciﬁc tables by gene of interest, with a brief
description in the text. As the frequency of genetic differences
varies between ethnic or geographic populations, each study is
based on a speciﬁc patient population to minimize heterogeneity.
Therefore, the tables also include critical details that give information
about the context (ethnic background) and likely strength (based on
sample size) of the study, to provide a source of reference.
Results
Polycystic ovary syndrome
PCOS affects about 1 in 10 women of reproductive age, and is the
most common endocrine condition in this group. The syndrome is
associated with multiple endocrinological and metabolic abnorm-
alities, with hyperandrogenaemia and anovulation as the central
hallmarks (The Rotterdam ESHRE/ASRM-Sponsored PCOS
Consensus Workshop Group, 2004a, b). About 80% of women
with PCOS have abnormal menstrual cycles (Conway et al.,
1989), many are anovulatory (Laven et al., 2002) and, in those
who manage to conceive successfully after treatment, there is an
increased risk of complications during pregnancy as well as neo-
natal complications (Boomsma et al., 2006).
Twin and familial studies suggest that there is a genetic com-
ponent to PCOS, with a polygenic pattern of inheritance (Jahanfar
andEden,1996;Diamanti-KandarakisandPiperi,2005;Fratantonio
et al., 2005). There is also a strong environmental component (e.g.
diet and exercise) (Abbott et al., 2002). A series of familial studies
conducted in the USA have demonstrated a strong linkage
between susceptibility to PCOS and the dinucleotide marker
D19S884 in the chromosomal region 19p13.2 (Urbanek et al.,
2000a, 2005, 2003; Stewart et al., 2006). The identity of the gene
or genetic element responsible for this effect is not yet known. As
complex traits such as PCOS result from the interaction of several
genetic variations with environmental factors, individual genetic
variations have a modest effect that is more difﬁcult to detect than
for monogenic traits.
The search for PCOS susceptibility genes hasfocused mainly on
genes involved in sex hormone regulation, insulin sensitivity, car-
diovascular risk or steroid biosynthesis and detoxiﬁcation
(Ehrmann, 2005; Escobar-Morreale et al., 2005; Fratantonio
et al., 2005). The results from these studies are summarized in
Tables I–IV and are described below.
Sex hormones and hormone regulators
Because PCOS is characterized by endocrinological abnormal-
ities, polymorphisms in genes encoding sex hormones or regula-
tors of their activity have been investigated (Table I).
Hormone receptors. Two variants in the gene encoding the b2
adrenergic receptor (ADRB2) were studied in Japanese women:
the p.Q27E variant was linked to PCOS susceptibility, but the
p.R16G variant was not (Kurabayashi et al., 2006). Within the
b3 adrenergic receptor (ADRB3) gene, the p.W64R polymorphism
does not appear to confer an increased risk of PCOS (Perez-Bravo
et al., 2005; Kurabayashi et al., 2006), although it may affect tri-
glyceride regulation in women with this condition (Perez-Bravo
et al., 2005). Conﬂicting ﬁndings have been reported from
studies investigating the association between the length of the
CAG repeat microsatellite in the androgen receptor (AR) gene
and PCOS susceptibility (Hickey et al., 2002; Jaaskelainen
et al., 2005); however, short alleles of this microsatellite appear
to be associated with increased androgenic activity (Mifsud
et al., 2000), and this may lead to PCOS. One study has shown
that an AccI restriction fragment length polymorphism (RFLP)
in the gene that encodes the beta subunit of the gonadotrophin
follicle-stimulating hormone (FSHB) may be associated with
PCOS susceptibility (Tong et al., 2000). A larger number of
studies have investigated polymorphisms in the gene that
encodes the receptor for FSH rather than the gene for the
hormone itself. The FSHR gene contains two important SNPs in
exon 10, which are in linkage disequilibrium and change two
amino acids at positions 307 and 680. However, although the
p.N680S genotype inﬂuences ovarian response (see section on
ovarian response to gonadotrophins), this common polymorphism
does not seem to play a major role in PCOS. In Japanese women
with PCOS, the S allele was more prevalent than in normal sub-
jects (Sudo et al., 2002), but no differential allelic distribution
was found in Caucasian (Conway et al., 1999) or Chinese
women (Tong et al., 2001).
Sex hormone-binding globulin. Women with PCOS have subnor-
mal levels of SHBG, and a microsatellite repeat in the promoter
of the SHBG gene has been linked to PCOS susceptibility in
Greek (Xita et al., 2003) but not in Slovenian (Ferk et al., 2007)
women, although in both populations, serum SHBG levels were
strongly inﬂuenced by the genotype. The p.D327N polymorphism
in this gene was not found to inﬂuence PCOS susceptibility in
studies in Slovenia or the Czech Republic (Bendlova et al.,
2007; Ferk et al., 2007).
Regulators of hormone activity. Studies of the following genes that
also encode hormones or proteins regulating hormone activity
have failed to show an association with PCOS susceptibility:
Dopamine D3 receptor (DRD3) (Kahsar-Miller et al., 1999), fol-
listatin (FST) (Urbanek et al., 2000b; Calvo et al., 2001; Jones
et al., 2007), guanine nucleotide-binding protein G (s) subunit
alpha (GNAS) (Hahn et al., 2006), leptin receptor (LEPR)
(Oksanen et al., 2000) and luteinizing hormone (LHB) (Rajkhowa
et al., 1995; Elter et al., 1999). However, there was an association
between phenotype and two of the SNPs investigated in the FST
gene (Jones et al., 2007). Furthermore, although not associated
with susceptibility, the genotype distribution of the signal trans-
duction protein gene GNAS was found to be associated with
body mass index (BMI) and insulin resistance in women with
PCOS (Hahn et al., 2006; Jones et al., 2007).
Steroid metabolism and biosynthesis
Several studies have investigated whether polymorphisms in
enzymes involved in the biosynthesis and metabolism of sex
steroids confer PCOS susceptibility (Table II).
Sex steroid synthesis. Type 5 17b-hydroxysteroid dehydrogenase
is an important enzyme for testosterone biosynthesis, and a poly-
morphism in the gene encoding this enzyme (AKR1C3) has been
Polymorphisms and PCOS
461Table I. Polymorphisms of genes encoding sex hormones and hormone regulators.
Gene (locus, protein name and its
function)
Variant Association with susceptibility Phenotype
Name dbSNP ID Positive (number of
cases, number of
controls)
Negative (number of cases,
number of controls)
ADRB2 (5q31-q32, b2 adrenic receptor:
calcium signalling, may play a role in
insulin resistance)
p.R16G rs1042713 Japanese women (59, 97)
(Kurabayashi et al., 2006)
p.Q27E rs1042714 Japanese women (59, 97)
(Kurabayashi et al.,
2006)
ADRB3 (8p12-p11.2, b3 adrenic receptor:
hormone receptor)
p.W64R rs4994 Chilean women (106, 82)
(Perez-Bravo et al., 2005)
Chilean women—triglyceride
levels (106, 82) (Perez-Bravo
et al., 2005)
Japanese women (59, 97)
(Kurabayashi et al., 2006)
AR (Xq11.2-q12, androgen receptor:
hormone receptor)
CAG repeat rs5902610, rs25885096 Australian women (122,
83) (Hickey et al., 2002)
Finnish women (106, 112)
(Jaaskelainen et al., 2005)
Asian women—T levels (91,
12) (Mifsud et al., 2000)
DRD3 (3q13.3, dopamine D3 receptor:
regulates sex hormone secretion)
MscI RFLP (p.S9G) rs6280 Caucasian women (152, 96)
(Kahsar-Miller et al., 1999)
FSHB (11p13, follicle-stimulating hormone
b: sex hormone)
AccI RFLP (1736T/C) rs6169 Chinese women (135,
105) (Tong et al., 2000)
FSHR (2p21-p16, follicle-stimulating
hormone receptor: hormone receptor)
p.A307T rs6165 Japanese women (18,
258) (Sudo et al., 2002)
Chinese women (124, 236) (Tong
et al., 2001) Caucasian women
(93, 51) (Conway et al., 1999)
p.N680S rs6166 Japanese women (18,
258) (Sudo et al., 2002)
Chinese women (124, 236) (Tong
et al., 2001)
Caucasian women (93, 51)
(Conway et al., 1999)
FST (5q11.2, follistatin: inhibits
follicle-stimulating hormone release)
951G/A rs1746136 Spanish women (34, 15) (Calvo
et al., 2001)
343xT/A rs722910 Families, mixed descent (249
a)
(Urbanek et al., 2000b)
D5S474, D5S822, D5S628 Families, mixed descent (249
a)
(Urbanek et al., 2000b)
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2rs3797297 Australian women (173, 107)
(Jones et al., 2007)
Australian women—FAI and
SHBG levels (173, 107)
(Jones et al., 2007)
rs11745088 Australian women (173, 107)
(Jones et al., 2007)
Australian women—DHES-S
level (173, 107) (Jones et al.,
2007)
rs1423560, rs3203788,
rs1062809, rs1127760,
rs1127761
Australian women (173, 107)
(Jones et al., 2007)
GNAS (20q13.32, guanine
nucleotide-binding protein G(s) subunit
alpha isoform: GPCR signal transduction)
393T/C rs7121 German caucasian women (278,
209) (Hahn et al., 2006)
German caucasian women—
BMI/weight, insulin
resistance (278, 209) (Hahn
et al., 2006)
LEPR (1p31, leptin receptor: regulates
hormone activity)
p.K109R rs1137100 Finnish women (38, 122)
(Oksanen et al., 2000)
p.R223Q rs1137101 Finnish women (38, 122)
(Oksanen et al., 2000)
p.N656K rs8179183 Finnish women (38, 122)
(Oksanen et al., 2000)
ins/del CTTTA in 30-UTR Finnish women (38, 122)
(Oksanen et al., 2000)
LHB (19q13.32, luteinizing hormone: sex
hormone)
p.W8R (p.W28R) rs1800447 Turkish women (30, 30) (Elter
et al., 1999),
UK women (153, 212) (Rajkhowa
et al., 1995)
p.I15T (p.I35T) rs3434826 Turkish women (30, 30) (Elter
et al., 1999), UK women (153,
212) (Rajkhowa et al., 1995)
SHBG (17p13-p12, sex hormone-binding
globulin: mediates hormonal activity)
TAAAA repeat rs35785886 Greek women (185, 324)
(Xita et al., 2003)
Slovenian women (123, 110) (Ferk
et al., 2007)
Greek women—FAI and
SHBG levels (185, 324)
(Xita et al., 2003)
Sloven women—SHBG
levels (123, 110) (Ferk et al.,
2007)
p.D327 N rs6259 Czech Republic women (248, 109)
(Bendlova et al., 2007)
Slovenian women (123, 110) (Ferk
et al., 2007)
The list (ordered alphabetically) shows genes that have been investigated for their role in polycystic ovary syndrome. Studies showing positive or no associations of these genes with disease susceptibility and
positive associations with phenotype (clinical characteristics of the condition, e.g. endocrinological abnormalities) are presented. Genes are listed alphabetically.
aNumber of PCOS families. BMI, body mass
index; PCOS, polycystic ovary syndrome; RFLP, restriction fragment length polymorphism.
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3Table II. Polymorphisms of genes encoding enzymes involved in steroid metabolism and biosynthesis.
Gene (locus, protein name and its function) Variant Association with susceptibility Phenotype Treatment
response
Name dbSNP ID Positive (number of cases, number of
controls)
Negative (number of cases,
number of controls)
AKR1C3 (17q11-q21, 5 17b-hydroxysteroid
dehydrogenase: testosterone biosynthesis,
oestrogen metabolism)
271G/A rs3763676 North American women (121, 128)
(Qin et al., 2006)
CYP1A1 (15q22-q24, cytochrome P450 1A1
enzyme: steroid biosynthesis, oestrogen
metabolism, Phase I detoxiﬁcation)
MspI RFLP
(6235T/C)
(3801T/C)
rs4646903 South Indian women (180, 72) (Babu
et al., 2004)
CYP11A1 (15q23-q24, cytochrome P450 11A
enzyme: steroid biosynthesis)
TTTTA VNTR
(D15S520)
Greek women (80, 90)
(Diamanti-Kandarakis et al., 2000)
Chinese women— BMI (201,
147) (Hahn et al., 2006; Wang
et al., 2006a),
UK (371, 350) and Finnish women
(1589
a) (Gaasenbeek et al., 2004)
UK women—T levels (97,
51aPCO, 59) (Gharani et al.,
1997)
Chinese women (201, 147) (Hahn
et al., 2006; Wang et al., 2006a)
UK women (97, 51aPCO, 59) (Gharani
et al., 1997)
AAAT repeat
(intron 1)
UK (371, 350) and Finnish women
(1589
a) (Gaasenbeek et al., 2004)
CYP11B2 (8q21-q22, aldosterone synthetase:
steroid biosynthesis, regulates ovarian renin–
angiotensin system)
2344C/T rs1799998 Chinese women (92, 60) (Zhao et al.,
2003)
CYP17A1 (10q24.3, 17a-hydroxylase:
oestrogen biosynthesis)
MspA1 RFLP
(234T/C)
rs743572 Polish women (55, 56) (Marszalek
et al., 2001)
Greek women (50, 50)
(Diamanti-Kandarakis et al., 1999)
UK women (69, 124)
(Techatraisak et al., 1997)
CYP19A1 (15q21.1, aromatase: steroid
biosynthesis)
TTTA VNTR
(D15S103)
UK women (97, 59) (Gharani
et al., 1997)
SNP44 rs12907866 Spanish women (186, 71) (Petry
et al., 2005)
SNP50 rs2414096 Spanish women—‘PCOS score’
(186, 71) (Petry et al., 2005)
SNP60 rs17601241 Spanish women (186, 71) (Petry
et al., 2005)
SNP64 rs4646 Spanish women (186, 71) (Petry
et al., 2005)
EPHX1 (1q42.1, microsomal epoxide
hydrolase: detoxiﬁcation, component of the
anti-oestrogen binding site complex)
p.Y113H rs1051740 Finnish women (rs1051740, rs2234922
haplotype) (112, 115) (Korhonen et al.,
2003b)
p.H139R rs2234922 Finnish women (rs1051740, rs2234922
haplotype) (112, 115) (Korhonen et al.,
2003b)
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4GATA6 (18q11.2, GATA binding protein 6:
transcription factor)
rs7235350,
rs9957475,
rs9944560,
rs3764962,
rs1941083
Australian women (173, 107)
(Jones et al., 2006)
GSTM1 (1p13.3, glutathione S-transferase M1:
phase 2 detoxiﬁcation)
Null deletion South Indian women (180, 72)
(Babu et al., 2004)
GSTT1 (22q11.23, glutathione S-transferase
T1: phase 2 detoxiﬁcation)
Null deletion South Indian women (180, 72)
(Babu et al., 2004)
H6PD (1p36, hexose-6 phosphate
dehydrogenase: steroid biosynthesis)
p.R453Q rs6688832 Spanish women (116, 76) (San Millan
et al., 2005)
UK women (191, 261) (Draper
et al., 2006)
Spanish women—basal F and
17OHP levels (116, 76) (San
Millan et al., 2005)
HSD11B1 (1q32-q41, 11b-hydroxysteroid
dehydrogenase: steroid biosynthesis)
83557ins/delA Spanish women (116, 76) (San
Millan et al., 2005)
UK women (202,263) (Draper
et al., 2006)
83597T/G rs12086634 UK women (202, 263) (Draper
et al., 2006)
HSD17B6 (12q13, 17b-hydroxysteroid
dehydrogenase 6: steroid biosynthesis)
rs898611 Australian women (173, 107) (Jones
et al., 2006)
Australian women—fasting
insulin and glucose levels, BMI
(173, 107) (Jones et al., 2006)
rs2277339, Australian women (173, 107)
rs10459246 (Jones et al., 2006)
rs7967600 Australian women (173, 107)
(Jones et al., 2006)
Australian women—fasting
insulin and glucose levels, BMI
(173, 107) (Jones et al., 2006)
rs1870673 Australian women (173, 107)
(Jones et al., 2006)
Australian women—BMI, T
levels (173, 107) (Jones et al.,
2006)
rs1227117 Australian women (173, 107)
(Jones et al., 2006)
Australian women—BMI (173,
107) (Jones et al., 2006)
SRD5A1 (5p15, 5 a-reductase isoform: steroid
biosynthesis)
Haplotype:
rs3797179,
rs39848
North American women (287, 187)
(Goodarzi et al., 2006)
North American women—
hirsutism, mFG score (287,
187) (Goodarzi et al., 2006)
Haplotype:
rs472402,
North American women—
hirsutism, mFG score (287,
187) (Goodarzi et al., 2006) rs2677933,
rs248805,
rs3822430,
rs10060745
SRD5A2 (2p23, 5 a-reductase isoform: Haplotype: North American women (287, 187)
(Goodarzi et al., 2006) steroid biosynthesis) rs11889731,
rs7571644,
rs12470143,
rs12467911,
rs2300697
Continued
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et al., 2006). A polymorphism in the CYP1A1 gene, which
encodes the enzyme cytochrome P450 1A1, has shown an associ-
ation with PCOS susceptibility in Indian women (Babu et al.,
2004). Cytochrome P450 11A (CYP11A1) is a rate-limiting
enzyme involved in the synthesis of androgens. Studies have indi-
cated that a pentanucleotide repeat in the gene is associated with
PCOS susceptibility (Gharani et al., 1997; Diamanti-Kandarakis
et al., 2000; Gaasenbeek et al., 2004; Wang et al., 2006a; Jones
et al., 2007). However, the large study of Gaasenbeek et al.
found only a weak association between the pentanucleotide
repeat and PCOS, and no association with another promoter
microsatellite (Gaasenbeek et al., 2004). In Chinese women, a
polymorphism in the promoter region of the aldosterone synthe-
tase gene (CYP11B2), which affects the balance of the ovarian
renin–angiotensin system, has been linked to PCOS susceptibility
(Zhao et al., 2003). A polymorphism in the gene for
17a-hydroxylase (CYP17A1), which is active in estrogen biosyn-
thesis, was not associated with PCOS susceptibility (Techatraisak
et al., 1997; Diamanti-Kandarakis et al., 1999; Marszalek et al.,
2001). The CYP19A1 gene encodes a key component of aroma-
tase, which catalyses the production of estrogens from androgens.
Although polymorphisms in this gene were not found to directly
affect susceptibility to PCOS in women from the UK (Gharani
et al., 1997) or Spain (Petry et al., 2005), the SNP50 polymorph-
ism in this gene did inﬂuence PCOS severity in the Spanish study
(Petry et al., 2005).
Sex steroid metabolism. The low activity haplotype (H113–R139)
of the gene encoding the detoxiﬁcation enzyme microsomal
epoxide hydrolase (EPHX1) was signiﬁcantly associated with
PCOS susceptibility in Finnish women (Korhonen et al., 2003b).
A variant of the hexose-6-phosphate dehydrogenase gene
(H6PD), which has been implicated in a rare cortisone reductase
deﬁciency that is characterized by a PCOS-like phenotype, has
been linked to PCOS susceptibility in Spanish (San Millan
et al., 2005), but not in UK women (Draper et al., 2006). Poly-
morphisms in the gene encoding 17b-hydroxysteroid dehydrogen-
ase 6 (HSD17B6) have been found to be associated with either
PCOS or with the clinical phenotype (Jones et al., 2006).
A North American genetic association study of the two isoforms
of the steroid biosynthesis enzyme 5a-reductase found that haplo-
types in both SRD5A1 and SRD5A2 were associated with PCOS
susceptibility, but that only variants in the SRD5A1 gene were
associated with severity of hirsutism (Goodarzi et al., 2006).
Polymorphisms in genes encoding 11b-hydroxysteroid dehy-
drogenase (HSD11B1) (San Millan et al., 2005; Draper et al.,
2006), the glutathione S-transferases M1 or T1 (GSTM1,
GSTT1) (Babu et al., 2004) and the transcription factor GATA-
binding protein 6 (GATA6) (Jones et al., 2006) have also been
investigated but failed to show an association with PCOS.
Genes involved in type 2 diabetes and cardiovascular disease
The increased risk of type 2 diabetes and cardiovascular disease in
women with PCOS has led to numerous association studies in
genes related to these diseases (Table III).
Adiponectin. Patients with obesity, type 2 diabetes, insulin resist-
ance or PCOS have abnormally low levels of adiponectin, and
therefore several studies have investigated the effect of two
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466Table III. Polymorphisms of genes encoding proteins involved in type 2 diabetes and cardiovascular disease.
Gene (locus, protein name and its
function)
Variant Association with susceptibility Phenotype Treatment
response
Name dbSNP ID Positive (number of cases,
number of controls)
Negative (number of cases,
number of controls)
Genes encoding proteins involved in insulin pathways
ADIPOQ (3q27, adiponectin:
mediates insulin resistance)
45G/T rs2241766 German women (57, 567)
(Haap et al., 2005)
Greek women (132, 100;
100, 140) (Panidis et al.,
2004; Xita et al., 2005)
Caucasian women (72, 42)
(San Millan et al., 2004)
Greek women—insulin level
(100, 140) (Panidis et al.,
2004; Xita et al., 2005)
Finnish women (143, 245)
(Heinonen et al., 2005)
276G/T rs1501299 Greek women (132, 100;
100, 140) (Panidis et al.,
2004; Xita et al., 2005)
Greek women—insulin
exposue, adiponectine levels,
BMI (100, 140) (Panidis
et al., 2004; Xita et al., 2005)
Caucasian women (72, 42)
(San Millan et al., 2004)
Finnish women (143, 245)
(Heinonen et al., 2005)
APOE (19q13.2, apolipoprotein E:
mediates insulin resistance)
3937C/T and
4075C/T (e2, e3
and e4 alleles)
rs429358þrs7412 Finnish women (58, 91)
(Heinonen et al., 2001)
CAPN10 (2q37.3, calpain-10:
mediates insulin resistance)
4841T/C
(UCSNP44)
rs2975760 Spanish women (148, 93)
(Gonzalez et al., 2003)
German women (57, 567)
(Haap et al., 2005)
Spanish women—hirsutism
score (81, 37)
(Escobar-Morreale et al.,
2002)
Spanish women (81, 37)
(Escobar-Morreale et al.,
2002)
4852G/A
(UCSNP43)
rs3792267 German women (57, 567)
(Haap et al., 2005)
Spanish women—hirsutism
score (81, 37)
(Escobar-Morreale et al.,
2002)
Spanish women (148, 93; 81,
37) (Gonzalez et al., 2003)
North American women
(181, 422) (Ehrmann et al.,
2002a)
7920ins/del32
bp (UCSNP19)
Spanish women (148, 93)
(Gonzalez et al., 2003)
North American women
(181, 422) (Ehrmann et al.,
2002a)
UCSNP45 rs41266971 Spanish women (81, 37)
(Escobar-Morreale et al., 2002)
German women (57, 567)
(Haap et al., 2005)
Continued
P
o
l
y
m
o
r
p
h
i
s
m
s
a
n
d
P
C
O
S
4
6
7Table III. Continued
Gene (locus, protein name and its
function)
Variant Association with susceptibility Phenotype Treatment
response
Name dbSNP ID Positive (number of cases,
number of controls)
Negative (number of cases,
number of controls)
UCSNP63 rs5030952 Spanish women (148, 93)
(Gonzalez et al., 2003)
Spanish women (148, 93)—
cholesterol level (Gonzalez
et al., 2003)
North American women
(181, 422) (Ehrmann et al.,
2002a)
ENPP1 (6q22-q23, plasma cell
differentiation antigen glycoprotein
(PC-1): mediates insulin resistance)
p.K121Q rs1044498 Finnish women (143, 115)
(Heinonen et al., 2004)
Caucasian women (72, 42)
(San Millan et al., 2004)
Japanese women (123, 180)
(Baba et al., 2007)
FOXC2 (16q22-16q24, forkhead box
C2: transcription factor, mediates
insulin resistance)
2512C/T rs34221221 German women (57, 567)
(Haap et al., 2005)
GYS1 (19q13.3, glycogen synthetase
1 (muscle): mediates insulin
resistance)
Xbal RFLP
(C/T)
rs8103451 UK women (90, 62)
(Rajkhowa et al., 1996)
IGF1 (12q22-q23, insulin-like growth
factor-1: insulin signalling)
CA repeat
(promoter)
Caucasian women (72, 42)
(San Millan et al., 2004)
IGF2 (11p15.5, insulin-like growth
factor-2: insulin signalling)
ApaI RFLP
(17200G/A)
rs680 Caucasian women (72, 42) (San
Millan et al., 2004)
IGF1R (15q26.3, insulin-like growth
factor-1 receptor: insulin signalling)
AGG repeat at
position 967
Caucasian women (72, 42)
(San Millan et al., 2004)
IGF2R (6q26, insulin-like growth
factor-2 receptor: insulin signalling)
ins/delACAA in
30 UTR
Caucasian women (72, 42)
(San Millan et al., 2004)
INS (11p15.5, insulin: hormone) VNTR UK women, linkage studies (54,
78 and 2 family-based linkage
studies; 74, 150) (Franks et al.,
1999; Michelmore et al., 2001)
UK (255 familiesþ185,
1062) and Finnish women
(530 [72 conﬁrmed by US],
1069) (Powell et al., 2005)
Spanish women (40, 38)
(Calvo et al., 2002)
Czech women (38, 22)
(Vankova et al., 2002)
INSR (19p13.3-p13.2, insulin
receptor: hormone regulation)
p.H1058H T/C
(3364T/C)
rs1799817 Chinese women (120, 40)
(Chen et al., 2004)
Non-obese North American
women (99, 136) (Siegel et al.,
2002)
Korean women (174, 93)
(Lee et al., 2006)
Chinese women—
weight/BMI (120, 40) (Chen
et al., 2004)
Korean women (134, 100) (Lee
et al., 2007)
p.C1008C T/C
(3128T/C)
No dbSNP ID Chinese women (109, 107) (Jin
et al., 2006)
Chinese women—insulin
sensitivity (109, 107) (Jin
et al., 2006)
109482A/G,
109665C/T,
No dbSNP ID,
rs6510959,
Korean women (134, 100)
(Lee et al., 2007)
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8125498A/G, rs2303672,
127527G/A, rs2059806,
143485G/C, rs2252673,
161822G/A, rs2860175,
168828T/A No dbSNP ID
176477C/T No dbSNP ID Korean women (134, 100) (Lee
et al., 2007)
IRS1 (2q36, insulin receptor
substrate-1: insulin signalling)
p.G972R rs1801278 Chilean women (146, 97)
(Sir-Petermann et al., 2004)
German women (57, 567)
(Haap et al., 2005)
Chilean women—insulin
resistance (146, 97)
(Sir-Petermann et al., 2004)
Metformin
response in
Turkish women
(60
a) (Ertunc
et al., 2005)
Japanese women (123, 180)
(Baba et al., 2007)
North American women
(227
a) (Ehrmann et al.,
2002b)
North American women, in
carriers of CYP21
heterozygous mutation (114,
95) (Witchel et al., 2005)
Turkish women (60, 60) (Dilek
et al., 2005)
Spanish caucasian women
(103, 48) (Villuendas et al.,
2005)
Spanish caucasian women—
BMI, insulin resistance (103,
48) (Villuendas et al., 2005)
Caucasian women (53, 102)
(El Mkadem et al., 2001)
Caucasian women—insulin
resistance (53, 102) (El
Mkadem et al., 2001)
IRS2 (13q34, insulin receptor
substrate-2: insulin signalling)
p.G1057D rs1805097 German women (57, 567)
(Haap et al., 2005)
Caucasian American
women—blood glucose level
(227
a) (Ehrmann et al.,
2002b)
Spanish caucasian women
(103, 48) (Villuendas et al.,
2005)
Caucasian women—blood
glucose level (53, 102) (El
Mkadem et al., 2001)
Caucasian women (53, 102)
(El Mkadem et al., 2001)
PON1 (7q21.3, paraoxonase 1:
antioxidant enzyme, linked to insulin
resistance and cardiovascular disease)
2108C/T rs705379 Caucasian women (72, 42) (San
Millan et al., 2004)
p.L55M rs854560 Caucasian women (72, 42)
(San Millan et al., 2004)
Caucasian women—BMI and
insulin resistance (72, 42)
(San Millan et al., 2004)
p.Q192R rs662 Caucasian women (72, 42)
(San Millan et al., 2004)
PPARG (3p25, peroxisome
proliferator-activated receptor-g:
transcription factor, mediates insulin
resistance, regulates CCL5
expression)
p.P12A rs1801282 Finnish women (135, 115)
(Korhonen et al., 2003a)
German women (57, 567)
(Haap et al., 2005)
Turkish women—glucose
metabolism (60, 60) (Tok
et al., 2005)
Caucasian women (72, 42)
(San Millan et al., 2004)
German women—insulin
sensitivity; hirsutism score
(102, 104) (Hahn et al.,
2005)
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Gene (locus, protein name and its
function)
Variant Association with susceptibility Phenotype Treatment
response
Name dbSNP ID Positive (number of cases,
number of controls)
Negative (number of cases,
number of controls)
Chinese women (201, 147)
(Wang et al., 2006b)
North American women—
insulin sensitivity (218
a)
(Hara et al., 2002)
North American women
(285, 187) (Antoine et al.,
2007)
Italian women (100, 100)
(Orio et al., 2003a)
p.H447H,
1431C/T
rs3856806 North American women
(285, 187) (Antoine et al.,
2007)
Italian women—BMI (100,
100) (Orio et al., 2003a)
PPARGC1A (4p15.2, peroxisome
proliferator-activated receptor gamma,
coactivator 1 alpha: transcriptional
coactivator for steroid receptors and
nuclear receptors)
p.S482G rs8192678 Chinese women (201, 147)
(Wang et al., 2006b)
PPP1R3A (7q31.1, protein
phosphatase-1: mediates insulin
resistance)
5b pi n s /del in
the 30UTR
(ARE-1/ARE-2)
rs5886683þrs5886684 North American women—
insulin sensitivity (186
a)
(Alcoser et al., 2004)
PTPN1 (20q13.1-q13.2, protein
tyrosine phosphatase 1B: insulin
signalling)
981C/T rs11575938 Caucasian women (72, 42)
(San Millan et al., 2004)
1484ins/delG Caucasian women (72, 42)
(San Millan et al., 2004)
RETN (19p13.2, resistin: mediates
insulin resistance)
2179C/G
(2180C/G)
rs1862513 Greek women (320, 180)
(Xita et al., 2004)
Greek women—BMI (320,
180) (Xita et al., 2004)
SORBS1 (10q23.3-q24.1, sorbin: may
play a role in insulin resistance)
p.T228A rs2281939 Caucasian women (72, 42)
(San Millan et al., 2004)
Caucasian women—BMI (72,
42) (San Millan et al., 2004)
Mediators of vascular function or genes linked to cardiovascular risk
AGT (1q42-q43, angiotensin I:
mediates vascular homeostasis)
p.M235T rs699 Italian women (95, 64) (Zulian
et al., 2005)
Italian women—insulin
sensitivity (95, 64) (Zulian
et al., 2005)
MTHFR (1p36.3,
methylenetetrahydrofolate reductase:
olate metabolism, linked to
cardiovascular disease)
677C/T
(p.A222V)
rs1801133 Italian women (70, 70) (Orio
et al., 2003b)
PLAT (8p12, tissue plasminogen
activator: ﬁbrinolysis system, linked
to cardiovascular disease)
Alu repeat
ins/del 311 bp
rs4646972 Turkish women (91, 100)
(Karadeniz et al., 2007)
Turkish women—cholesterol
and LDL levels (91, 100)
(Karadeniz et al., 2007)
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0SNPs in the adiponectin gene (ADIPOQ) on PCOS susceptibility.
Whereas there was an association with the 45G/T polymorphism
in German and Finnish women (Haap et al., 2005; Heinonen et al.,
2005), there was no association for this polymorphism or the
276G/T polymorphism in Greek or Caucasian women (Panidis
et al., 2004; San Millan et al., 2004; Heinonen et al., 2005; Xita
et al., 2005) (NB: 276G/T was not investigated by Haap et al.).
Both polymorphisms may, however, affect insulin levels (Xita
et al., 2005).
Calpain-10. The gene for the cysteine protease calpain-10
(CAPN10) is associated with type 2 diabetes, and potential associ-
ations between ﬁve different polymorphisms and PCOS have been
investigated. In the CAPN10 gene, two different Spanish studies
found an association between either the SNP UCSNP44 (Gonzalez
et al., 2003) or UCSNP45 (Escobar-Morreale et al., 2002) and
PCOS susceptibility. These associations were not observed in a
German study (Haap et al., 2005). No associations were found
between the UCSNP43, UCSNP19, UCSNP63 polymorphisms
and PCOS (Ehrmann et al., 2002a; Gonzalez et al., 2003),
although there were some links with the symptoms of PCOS
(Escobar-Morreale et al., 2002; Gonzalez et al., 2003).
Plasma cell differentiation antigen. Genes encoding components of
the insulin signalling system have been investigated in relation to
PCOS across a number of studies. Plasma cell differentiation
antigen glycoprotein (PC-1, also known as ENPP1, ectonucleotide
pyrophosphatase/phosphodiesterase 1) is a mediator of insulin
receptor signalling and has been implicated in insulin resistance.
However, studies investigating an association between PCOS sus-
ceptibility and the p.K121Q polymorphism have reported both
positive (Heinonen et al., 2004) and negative (San Millan et al.,
2004; Baba et al., 2007) results. Although early case–control
studies in the UK indicated a link between PCOS susceptibility
and the insulin gene variable number of tandem repeats microsa-
tellite length (Franks et al., 1999; Michelmore et al., 2001), a
large subsequent study in more than 3000 women from the UK
and Finland found no such association (Powell et al., 2005). In
addition, studies conducted in the Czech Republic (Vankova
et al., 2002) and Spain (Calvo et al., 2002) have found no associ-
ation between this variant and PCOS.
Insulin receptor gene. Three polymorphisms in the insulin receptor
gene (INSR) have shown a positive association with PCOS:
3364T/C (p.H1058H) in Chinese (Chen et al., 2004) and Ameri-
can women (Siegel et al., 2002), but not Korean women (Lee
et al., 2006); 3128T/C (p.C1008C) in Chinese women (Jin
et al., 2006); and 176477C/T in Korean women (Lee et al.,
2007). The 2007 study by Lee et al. investigated a total of nine
polymorphisms but only found an association with 176477C/T.
The 3364T/C and 3128T/C polymorphisms were also associated
with the phenotype of PCOS (Chen et al., 2004; Jin et al., 2006).
Insulin receptor substrates. The insulin receptor substrates IRS-1
and IRS-2 are proteins that participate in the insulin signal trans-
duction pathway. Extensive investigations on a possible associ-
ation between the p.G972R polymorphism in the IRS-1 gene and
PCOS have been carried out, with both postive (Sir-Petermann
et al., 2004; Dilek et al., 2005; Baba et al., 2007) and negative
(El Mkadem et al., 2001; Ehrmann et al., 2002b; Haap et al.,
2005; Villuendas et al., 2005) results. The polymorphism was
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Polymorphisms and PCOS
471Table IV. Polymorphisms of genes encoding proteins involved in tissue remodelling or inﬂammatory processes.
Gene (locus, protein name and its function) Variant Association with susceptibility Phenotype
Name dbSNP ID Positive (number of cases, number of
controls)
Negative (number of cases, number
of controls)
Genes involved in tissue remodeling
MMP1 (11q22.3, matrix metalloproteinase-1:
endometrial lesion formation)
1607ins/delG rs11292517 Caucasian women (62, 94) (Walch
et al., 2005b)
Inﬂammatory mediators
HLA-A (6p21.3, major histocompatibility
complex class I, A: antigen processing and
presentation)
A11 Japanese women (56, 237) (Kaibe
et al., 2006)
HLA-B (6p21.3, major histocompatibility
complex class I, B: antigen processing and
presentation)
B39 Protective effect in Japanese women
(56, 237) (Kaibe et al., 2006)
HLA-C (6p21.3, major histocompatibility
complex class I, C: antigen processing and
presentation)
All alleles Japanese women (56, 237) (Kaibe
et al., 2006)
HLA-DRB1 (6p21.3, major histocompatibility
complex class I, DR beta 1: antigen processing
and presentation)
*0403 Japanese women (68, 292) (Kaibe
et al., 2006)
HFE (6p21.3, haemochromatosis protein (MHC
class I family): antigen processing and
presentation, iron binding)
p.H63D rs1799945 Spanish women (78, 43)
(Botella-Carretero et al., 2006)
p.C282Y rs1800562 Spanish women (78, 43)
(Botella-Carretero et al., 2006)
IL1A (2q14, interleukin-1 alpha: cytokine) 2889C/T rs1800587 Austrian caucasian women (105,
102) (Kolbus et al., 2007)
Austrian caucasian women—FSH serum
level, LH/FSH ratio (105, 102) (Kolbus
et al., 2007)
IL1B (2q14, interleukin-1 beta: cytokine) 2511C/T,
exon 5
rs16944 Austrian caucasian women (105,
102) (Kolbus et al., 2007)
3953G/A
(exon5 TaqI
RFLP,
E1/E2)
rs1143634 Austrian caucasian women (105,
102) (Kolbus et al., 2007)
IL6 (7p21, interleukin-6: cytokine) 2597G/A rs1800797 Spanish caucasian women (85, 25)
(Villuendas et al., 2002)
2572G/C rs1800796 Spanish caucasian women (85, 25)
(Villuendas et al., 2002)
2174G/C rs1800795 Spanish caucasian women (85, 25)
(Villuendas et al., 2002)
Austrian caucasian women (62, 94)
(Walch et al., 2004)
Austrian caucasian women—BMI, T
levels, OGTT results (62, 94) (Walch
et al., 2004)
German women—androstendione levels
(50, 0) (Mohlig et al., 2004)
IL6R (1q22, interleukin-6 repector alpha:
cytokine receptor)
CA repeat Spanish women (88, 45)
(Escobar-Morreale et al., 2003)
IL6ST (5q11.2, gp130, interleukin-6 repector
beta: cytokine receptor)
p.G148R rs3729960 Spanish women (88, 45)
(Escobar-Morreale et al., 2003)
TNF (6p21.3, tumour necrosis factor alpha:
cytokine)
2850C/T
(2857C/T)
rs1799724 Cauasian Finnish women (87, 115)
(Korhonen et al., 2002)
Australian women—OGTT results (122,
28) (Milner et al., 1999)
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2associated with symptoms of PCOS across four different studies
(El Mkadem et al., 2001; Sir-Petermann et al., 2004; Villuendas
et al., 2005; Witchel et al., 2005). Metformin, an insulin-
sensitizing drug that is often used in women with PCOS to
induce ovulation, is believed to act via phosphorylation of IRS
proteins. This could explain why a study in Turkish women with
PCOS indicated that the IRS-1 genotype may inﬂuence a patient’s
response to metformin therapy (Ertunc et al., 2005). In contrast,
investigations into the p.G1057D polymorphism in the IRS-2
gene have failed to show an association with susceptibility to
PCOS (El Mkadem et al., 2001; Haap et al., 2005; Villuendas
et al., 2005), but have linked this polymorphism with blood
glucose levels in women with PCOS (El Mkadem et al., 2001;
Ehrmann et al., 2002b).
Insulin-like growth factors. An ApaI RFLP in the insulin-like
growth factor-2 (IGF-2) gene has been linked to PCOS suscepti-
bility in Caucasian women (San Millan et al., 2004), whereas poly-
morphisms in genes encoding IGF-1, IGF-1 receptor and IGF-2
receptor were not associated (San Millan et al., 2004). Of three
variants investigated in the paraoxonase gene (PON1) (San
Millan et al., 2004), the 2108C/T variant was linked to PCOS
susceptibility in Caucasian women. The p.L55M polymorphisms
was not associated with PCOS, but was linked with a higher BMI
and greater insulin resistance in women who were homozygotic for
the 55M polymorphism compared with carriers of the common
55L allele. This polymorphism is believed to contribute to impaired
insulin function by increasing levels of oxidative stress in women
with PCOS. The remaining polymorphism investigated (p.Q192R)
was associated with neither susceptibility nor phenotype.
Peroxisomeproliferator-activatedreceptor-g. Peroxisome proliferator-
activated receptor-g (PPARG) regulates the expression of several
anti-atherosclerotic proteins. One study of the polymorphism
p.P12A showed an association with PCOS susceptibility in
Finnish women (Korhonen et al., 2003a), but ﬁve other studies
found no such association (Orio et al., 2003a; San Millan et al.,
2004; Haap et al., 2005; Wang et al., 2006b; Antoine et al.,
2007). Three studies found effects on glucose metabolism or
insulin sensitivity in carriers of this polymorphism (Hara et al.,
2002; Hahn et al., 2005; Tok et al., 2005) and indications that gen-
otype also determines levels of hirsutism (Hahn et al., 2005). The
1431C/T (p.H447H) polymorphism in this gene has been linked to
obesity in women with PCOS (Orio et al., 2003a) but not to
susceptibility to PCOS (Antoine et al., 2007). So far, there has
only been a single study of the PPARG coactivator 1 alpha
(PPARGC1A) gene and no association was shown between the
polymorphism studied (p.S482G) and PCOS (Wang et al., 2006b).
Glucose metabolism and insulin resistance. An insertion/deletion
polymorphism in the AT-rich element within the 30-untranslated
region of the muscle-speciﬁc glycogen-targeting subunit of the
protein phosphatase-1 gene (PPP1R3A), which has been associ-
ated with insulin resistance and diabetes, has been shown to inﬂu-
ence insulin resistance and androgen levels in women with PCOS
(Alcoser et al., 2004). Also related to the phenotype of PCOS is
the 2179C/G polymorphism in the promoter region of the resistin
gene (RETN) (Xita et al., 2004) and the p.T228A polymorphism in
the sorbin and SH3 domain containing 1 (SORBS1) gene (San
Millan et al., 2004). Both were linked to higher BMI in carriers,
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473but neither was linked with susceptibility (San Millan et al., 2004;
Xita et al., 2004).
A number of variants of other genes involved in insulin resist-
ance, type 2 diabetes and/or obesity have been investigated but
failed to show an association with PCOS: apolipoprotein E
(APOE) (Heinonen et al., 2001), forkhead box C2 (FOXC2)
(Haap et al., 2005), glycogen synthetase 1 (GYS1) (Rajkhowa
et al., 1996) and protein tyrosine phosphatase 1B (PTPN1) (San
Millan et al., 2004).
Genes linked to cardiovascular risk. Polymorphisms in a limited
number of genes linked to cardiovascular risk have been studied
to assess a possible role in PCOS (Table III). In one study, the
p.M235T polymorphism in the gene encoding angiotensin
I( AGT), a potent vasoconstrictor, was linked to PCOS suscepti-
bility and a genotype-dependent difference was seen in insulin
sensitivity in women with PCOS (Zulian et al., 2005). Methylene-
tetrahydrofolate reductase (MTHFR) is an enzyme involved in the
homocysteine pathway, and the p.A222V polymorphism in the
MTHFR gene increases circulating homocysteine levels. As elev-
ated levels of plasma homocysteine are associated with an
increased risk of cardiovascular disease, a study investigated
whether this polymorphism increases PCOS susceptibility in
Italian women, but failed to show an effect (Orio et al., 2003b).
As part of the ﬁbrinolytic system, the gene encoding tissue plasmi-
nogen activator (PLAT) has been investigated in relation to PCOS.
Although no association between the Alu repeat insertion/deletion
and susceptibility was found, PCOS patients that were homozygous
for the insertion (i/i genotype) had lower levels of low-density and
total cholesterol thanother genotypes (Karadenizetal.,2007).Plas-
minogenactivatorinhibitor-1(SERPINE1)isalsoinvolvedinblood
coagulation and has been implicated in cardiovascular disease. The
4G/5G polymorphism in the SERPINE1 gene has been linked with
PCOS susceptibility in one study (Diamanti-Kandarakis et al.,
2004), but no association was found in three other studies (San
Millan et al., 2004; Walch et al., 2005a; Karadeniz et al., 2007).
Women with PCOS who are carriers of the polymorphism were,
however, found to have an increased risk of miscarriage (Glueck
et al., 1999) and higher plasminogen activator inhibitor-1 levels
(Diamanti-Kandarakis et al., 2004).
Genes involved in tissue remodelling and inﬂammatory processes
Tissue remodelling. Matrix metalloproteinases (MMPs) are
thought to play a critical role in the remodelling of the extracellu-
lar matrix during follicular development (Goldman and Shalev,
2004). The 1607G insertion/deletion polymorphism in the
MMP1 gene has been associated with an increased risk of PCOS
in Caucasian women (Walch et al., 2005b) (Table IV). The associ-
ation of genes of the histocompatibility family with PCOS has
been studied in Japanese women. Whereas women with PCOS
were more likely to be carriers of the HLA-A11 or
HLA-DRB1*0403 alleles, they were less likely to be carriers of
the HLA-B39 allele when compared with healthy individuals (indi-
cating a protective effect). No association was found for the alleles
tested within HLA-C (Kaibe et al., 2006). No association was
found between two polymorphisms in the gene encoding haemo-
chromatosis protein, in the MHC Class I family (HFE), and
PCOS (Botella-Carretero et al., 2006).
Inﬂammatory cytokines. Circulating levels of several inﬂammatory
cytokines, including tumour necrosis factor-a (TNF-a) and
interleukin-6 (IL-6), correlate with insulin resistance and obesity
(Milner et al., 1999; Mohlig et al., 2004). It has also been proposed
that another inﬂammatory cytokine, IL-1, inﬂuences the processes
of ovulation, fertilization and implantation. A study in Austrian
women showed that the 2889C/T polymorphism in the IL1A
gene is associated with PCOS, which was not the case for the
2511C/T and 3953G/A polymorphisms in the IL1B gene
(Kolbus et al., 2007). Within the interleukin-6 (IL6) gene, the
597G/A polymorphism has been shown to be associated with
PCOS susceptibility (Villuendas et al., 2002); the 572G/C poly-
morphism not associated (Villuendas et al., 2002) and the
2174G/C was both associated with susceptibility (Villuendas
et al., 2002) and not associated with (Walch et al., 2004), but
related to, the PCOS phenotype (Mohlig et al., 2004; Walch
et al., 2004). An investigation into polymorphisms in the genes of
the IL-6 receptor complex found no association between the pre-
sence of a microsatellite CA repeat in the IL6R gene, but an associ-
ation between PCOS and the p.G148R polymorphism in the IL-6
signal transducer (IL6ST) gene (Escobar-Morreale et al., 2003).
Polymorphisms in the promoter region of the TNF-a gene
(TNF) do not appear to affect PCOS susceptibility (Milner et al.,
1999; Mao et al., 2000; Korhonen et al., 2002), but the 2308G/
A polymorphism is linked with glucose tolerance in women with
PCOS (Milner et al., 1999). The actions of TNF-a are mainly
mediated by type 1 or type 2 TNF receptors. Of the ﬁve poly-
morphisms in the TNF receptor 2 gene (TNFRSF1B) investigated
in relation to PCOS in Spanish and Italian women, only p.M196R
was found to be associated with PCOS susceptibility and hyperan-
drogenism, but the other four polymorphisms investigated were
not (Peral et al., 2002).
Ovarian response to gonadotrophins
Ovarian stimulation is usually performed by administering exo-
genousFSHfollowingpituitarydown-regulation.Ovarianresponse
toFSH, however,varieswidely among womenundergoingovarian
stimulation(Georgiouetal.,1997)withwide-reachingclinicalcon-
sequences. If ovarian response to stimulation is insufﬁcient, the
cycle may need to be cancelled. Similarly, if ovarian response is
excessive, cycle cancellation may be necessary to avoid the risk
of ovarian hyperstimulation syndrome (OHSS), a potentially life-
threatening complication. Application of pharmacogenetics to the
problem of predicting ovarian response utilizes information about
the genetic make-up of an individual patient. This information
may then be used in conjunction with existing clinical factors to
predict treatment response (Fauser et al., 2008).
FSH receptor
FSH induces the proliferation of granulosa cells and the synthesis
of the androgen-converting enzyme aromatase, and also plays a
crucial role in secondary follicle recruitment and selection of the
dominant follicle (Fauser and Van Heusden, 1997). The action
of FSH is mediated by FSHR, a member of the G-protein-coupled
receptor family, which is expressed solely by granulosa cells. The
FSHR gene harbours more than 900 SNPs, arranged in two major
linkage disequilibrium blocks (Fig. 3). Two non-synonymous
SNPs in strong linkage disequilibrium (p.A307T and p.N680S)
Simoni et al.
474have been identiﬁed in exon 10 of the FSHR gene (Simoni et al.,
1999). As the interaction between FSH and its receptor plays a key
role in ovarian stimulation, a number of groups have investigated
the effect of polymorphisms in the FSHR gene on ovarian response
(Table V).
Studies in women with normal ovarian function demonstrate
convincingly that SNPs in exon 10 modulate FSHR function and
the ovarian response to FSH. This effect was ﬁrst observed in a
partly retrospective, non-randomized study of German women
undergoing controlled ovarian hyperstimulation for assisted repro-
duction. The amount of FSH needed for controlled ovarian hyper-
stimulation to achieve similar peak estradiol levels was
signiﬁcantly lower in women with the N/N genotype at position
680 of the FSHR gene compared with women carrying the S/S
or N/S genotypes, indicating a lower ovarian sensitivity to FSH
in vivo for the S680 allele (Perez Mayorga et al., 2000). Similar
results were later obtained by other investigators who studied
populations from different ethnic backgrounds (Sudo et al.,
2002; de Castro et al., 2003, 2004; Behre et al., 2005; Falconer
et al., 2005; Jun et al., 2006; Loutradis et al., 2006). In accordance
with a genetic control of FSHR p.N680S genotype status on in
vitro fertilization (IVF) outcome, de Castro et al. (2003) reported
that women with the S/S genotype have signiﬁcantly higher rates
of cycle cancellation and poor response compared with carriers of
the N/So rN /N genotypes. These consistent ﬁndings in various
populations indicate that the effects of the FSHR p.N680S poly-
morphism are independent of ethnic background and may also
be present in other, previously uninvestigated, populations.
Recently, it was shown that in women undergoing IVF treatment,
the clinical pregnancy rate in women with the N/N genotype is
signiﬁcantly higher compared with those with the S/S genotype
(Jun et al., 2006). However, another study using a similar study
design showed opposite results, with higher pregnancy rates
in women with the S/S genotype (Klinkert et al., 2006)
(Table VI). These contrasting data should be interpreted with
caution, and larger, well-designed and properly powered studies
should be conducted before drawing conclusions about the
effects of the FSHR genotype on pregnancy rates.
In a study involving menstrual cycle monitoring in women with
normal, mono-ovulatory cycles, Greb et al. (2005) were able to
show that during the luteo-follicular transition, serum levels of
estradiol, progesterone and inhibin A were signiﬁcantly lower
and FSH started to rise earlier in women with the S/S genotype
compared with women who carried the N/N genotype for the
FSHR p.N680S polymorphism (Fig. 4). In addition, FSH levels
were steadily and signiﬁcantly higher during the follicular phase
in the S/S genotype group, whereas no differences were observed
between groups with regard to estradiol, inhibin B and growth
velocity of the dominant follicle, showing that higher levels of
endogenous FSH are necessary to achieve ovulation in carriers of
the S/S genotype. Menstrual cycles were signiﬁcantly longer in
women with the S/S genotype, with a difference of about 2 days
between these women and those with the N/N genotype. Thus,
this study demonstrated that the S/S genotype results in a higher
ovarian threshold for FSH, decreased negative feedback to the pitu-
itary and a longer menstrual cycle (Greb et al., 2005). Other studies
have observed that the genotype for the codon 680 polymorphism
was associated with differences in cycle length (Perez Mayorga
et al., 2000), basal FSH levels (Sudo et al., 2002; Laven et al.,
2003; Falconer et al., 2005; Jun et al., 2006; Loutradis et al.,
Figure 3: LD plot of the genomic region on chromosome 2 harbouring the FSHR gene, obtained from the HapMap website (www.hapmap.org).
More than900 SNPs are currently listedin the National Centre for Biotechnology Information SNPdatabase. These SNPs are groupedinto two major LD blocks (red
triangles). FSHR, follicle-stimulating hormone receptor; LD, linkage disequilibrium.
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475Table V. Polymorphisms in genes encoding sex hormones and hormone regulators, enzymes involved in metabolism and biosynthesis, or paracrine factors.
Gene Locus Protein name Protein function Variant Association with ovarian response Phenotype (cases, controls)
Name dbSNP ID Positive (cases,
controls)
Negative (cases,
controls)
Sex hormones and hormone regulators
AMH 19p13.3 Anti-Mu ¨llerian hormone Hormone p.I49S rs10407022 Caucasian women—E2 levels (53, 45)
(Kevenaar et al., 2007)
AMHR2 12q13 Anti-Mu ¨llerian hormone type
II receptor
Hormone receptor –482A/G rs2002555 Caucasian women—E2 levels levels
(53, 45) (Kevenaar et al., 2007)
ESR1 6q25.1 Oestrogen receptor a Hormone receptor PvuII RFLP
(2397T/C)
(g.938T/C)
rs2234693 Spanish women (170)
(Mao et al., 2000; de
Castro et al., 2004)
Caucasian women—follicule/oocyte
ratio, pregnancy rate (100, 100)
(Georgiou et al., 1997)
Chinese women (200,
200) (Sundarrajan
et al., 1999)
Chinese women—serum oestratdiol
levels, follicule/oocyte ratio, pregnancy
rate (200, 200) (Sundarrajan et al.,
1999)
ESR2 14q23.2 Oestrogen receptor b Hormone receptor AluI RFLP
(1730A/G)
(39A/G)
rs4986938 Spanish women (170)
(Mao et al., 2000; de
Castro et al., 2004)
FSHR 2p21-p16 Follicle-stimulating hormone
receptor
Hormone receptor p.N680S (in
complete LD
with p.A307T,
rs6165)
rs6166 German women (93)
(Perez Mayorga
et al., 2000; Behre
et al., 2005)
Dutch women (105)
(Klinkert et al., 2006)
German women—peak oestradiol levels
(93) (Behre et al., 2005)
Japanese women (58)
(Sudo et al., 2002)
German women—circulating FSH,
levels, number of follicules, lutheal
phase and menstrual cycle length (23)
(Perez Mayorga et al., 2000; Greb
et al., 2005)
Spanish women (102)
(de Castro et al.,
2003; de Castro
et al., 2004)
Japanese women (58)—basal FSH
(Sudo et al., 2002)
Korean women (263)
(Jun et al., 2006)
Dutch women (148) (Laven et al.,
2003)
Swedish women (68) (Falconer et al.,
2005)
Greek women (125
(Loutradis et al.,
2006)
Korean women—basal FSH, pregnancy
rate (263) (Jun et al., 2006)
Greek women (125)—FSH levels,
follicule and oocyte number (Loutradis
et al., 2006)
Dutch women—pregnancy rate (105)
(Klinkert et al., 2006)
Enzymes involved in metabolism and biosynthesis
CYP19A1 15q21.1 Aromatase Steroid biosynthesis 1672C/T rs10046 Spanish women (170)
(de Castro et al.,
2004)
Paracrine factors
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62006), pregnancy rates (Jun et al., 2006; Klinkert et al., 2006) and
follicular/oocyte number (Loutradis et al., 2006) (Table V).
Behre et al. (2005) conducted a prospective interventional study
using a randomized controlled trial design and showed that the
codon 680 polymorphism of the FSHR gene caused a differential
estradiol response to FSH. In this study, the same FSH dose for
ovarian hyperstimulation resulted in signiﬁcantly lower serum
levels of estradiol in women with the S/S genotype than in
women with the N/N genotype. This lower response could be
overcome by increasing the FSH dose (Behre et al., 2005)
(Fig. 5). Despite differences in estradiol levels, no signiﬁcant
differences were detected in the number of follicles or retrieved
oocytes, fertilization rate, cumulative embryo score or pregnancy
rate. This ﬁnding suggests that, using standard protocols, FSH
might be overdosed in individual women, which may put them
at risk of OHSS. Indeed, a retrospective association study demon-
strated that the FSHR S680 allele was represented to a higher
degree in women developing OHSS, and that the N680
allele was associated signiﬁcantly with the severity of OHSS
(Daelemans et al., 2004). Since OHSS is relatively rare, none of
the studies performed so far in individual centres have sufﬁcient
power to demonstrate or refute convincingly any association
with the FSHR gene; this is an issue that should be analysed retro-
spectively in a multicentre study.
Taken together, these data indicate that the FSHR gene may
play a signiﬁcant role in the success of ovarian stimulation.
Women with the FSHR S680 allele comprise 60–75% of
women undergoing IVF (allelic distribution is similar to that of
the general population), and are characterized by higher basal
FSH serum concentrations, the need for a higher amount of
exogenous FSH and a higher risk of hypo- or hyper-response.
Thus, genotyping the FSHR p.N680S polymorphism may
provide a means of identifying a population of poor responders
before IVF procedures are initiated. Since the basis of the poor
responder status of these women is a reduced response of the
FSHR to FSH stimulation, a stimulation protocol designed to over-
come the partial resistance to FSH response should be sufﬁcient to
improve signiﬁcantly the success of IVF in these women. The
clinical effectiveness of such an approach should be conﬁrmed
in randomized controlled trials.
It is important to note that studies in women with ovarian dys-
functiondidnotﬁndanyassociationbetweenFSHRpolymorphisms
and ovarian response to FSH; e.g. in premature ovarian failure
(Conway et al., 1999; Sundblad et al., 2004). No signiﬁcant differ-
ence in the FSH dose needed for monofollicular development was
detected between women with different FSHR genotypes in a non-
randomized trial and normogonadotrophic anovulatory women
treated with low-dose FSH for ovulation induction (Laven et al.,
2003). Therefore, it seems that the differential estradiol response
caused by different FSHR alleles is evident so far only in women
with normal ovarian function. Another study demonstrated that
the S680 allele is signiﬁcantly more frequent in women with
a normal menstrual cycle and elevated FSH levels than in women
with normal FSH levels, corroborating the idea of a higher FSH
threshold (de Koning et al., 2006). Finally, an intriguing association
between the A307–S680 haplotype and ovarian cancer suscepti-
bility was recently reported (Yang et al., 2006).
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477Other genes
In addition to studies investigating the inﬂuence of FSHR geno-
type on ovarian responsiveness, other genetic factors have been
analysed and reported to be involved in modulating ovarian
sensitivity to FSH. Important candidates are polymorphisms in
the ER1 (Georgiou et al., 1997; Sundarrajan et al., 1999; de
Castro et al., 2004), and ER2 genes (de Castro et al., 2004) as
well as in the anti-Mu ¨llerian hormone (AMH) and AMH type II
receptor genes (Kevenaar et al., 2007) and in MTHFR (Thaler
et al., 2006; Rosen et al., 2007). As ovarian responsiveness to
FSH may be a polygenic trait, future studies should investigate
the combined role of all these factors in large numbers of well-
characterized patients undergoing ovarian hyperstimulation,
using stringent genetic epidemiological criteria.
Finally, several studies have explored the effects of polymorph-
isms in genes for metabolic enzymes on ovarian response
(Table V). De Castro et al. (2004) studied the 1672C/T poly-
morphism in the CYP19A1 gene, which encodes an enzyme
involved in estrogen synthesis, and found that it does not inﬂuence
ovarian response to exogenous FSH. Bone morphogenetic protein
15 (BMP-15), a member of the transforming growth factor-b
superfamily, is a paracrine factor expressed exclusively in the
ovaries and is involved in oocyte and follicular development.
A recent study investigated the association between OHSS and
polymorphisms in the BMP15 gene (Moron et al., 2006). Although
individual polymorphisms did not show a strong association with
the risk of OHSS, the TGGG haplotype was a risk factor and the
CCAA haplotype was found to confer protection against OHSS
(Moron et al., 2006).
Discussion
This systematic review emphasizes the inconsistency of results
obtained by studies that have investigated associations between
polymorphisms and PCOS or ovarian response. This may be due
to methodological reasons, such as population stratiﬁcation
(genetic heterogeneity, population history), inappropriate disease/
trait deﬁnition, subject selection issues or chance ﬁndings. One of
the major problems with candidate gene studies concerns sample
size, which is frequently insufﬁcient. The sample sizes of many
such studies have been calculated based on knowledge acquired
while studying monogenic traits, which have a very strong effect.
Unlikemonogenetic traits, complex traits result fromthe interaction
of several genetic variations and environmental factors, thus indi-
vidual genetic variations have a much more modest effect
(Lander and Schork, 1994). This may not have been taken into con-
sideration, resulting in studies that are too small to reveal a genetic
association in the context of a complex trait. Furthermore, it has
been clearly demonstrated that studies with small populations,
those that investigate a genetic variation with a small effect, or
those that have a ﬂexible design that is prone to bias are less
likely to be replicated (Ioannidis, 2005). Similar conclusions were
drawn by Gorroochurn et al. (2007), who showed that for
commonly observed P-value thresholds (P ¼ 0.02–0.01, when
a ¼ 0.05), replication probabilities are surprisingly low (around
60–70% chance of replication).
Inconsistent results may also be due to characteristics inherent to
polymorphisms, such as incomplete penetrance, genetic heterogen-
eity and gene–geneorgene–environment interactions.Other short-
comings of the use of candidate genes/markers to study association
include the fact that only a very tiny part of the genome is being
studied, and this is done independently of any interactions that
may be involved. In addition, candidate gene selection relies on
prior knowledge, making it impossible to reveal an association
with genes that have unknown function or that have not been
known to be implicated in the disease/trait being studied.
To overcome some of these limitations, the use of genome-wide
scans is an experimental tool that is becoming an increasingly rea-
listic option. Over the past 5–10 years, reﬁnement of technology
involving polymerase chain reaction, development of microarray
technology and the remarkable progress in the characterization
of the human genome sequence have enabled the study of thou-
sands of DNA variations in a single experiment. Commercial
genotyping tools currently allow the study of almost a million
SNPs per sample in a single assay, representing roughly 10% of
the estimated total number of SNPs in the human genome.
Although not all known SNPs are represented on one genotyping
microarray, linkage disequilibrium allows nearly 90% of the
human genome to be studied with current technology (Schork
et al., 2000; Locke et al., 2006; Roeder et al., 2006). Therefore,
by performing an assay for a particular SNP, it is also possible
to indirectly test for the presence of other variants that are in
linkage disequilibrium. Although less advanced, the same technol-
ogy is also being used to study quantitative (or copy number) gene
variationonagenome-widebasis;thistypeofvariationhas recently
been found to impact a much larger part of the genome than orig-
inally thought (Iafrate et al., 2004). Before this technique offers
clinically useful data, however, key methodological points must
be addressed. These include increasing the sample size compared
with single gene/marker studies and resolving statistical problems
inherent to multiple testing. Although it is obvious that a number
of the studies reviewed had a small sample size, it is quite difﬁcult
to give a generic sample size that will ﬁt all studies, as this depends
on the frequency and number of the markers being tested and the
importance of the genetic effect of the associated marker; genome-
Table VI. Comparison of the study designs and outcomes of two conﬂicting studies investigating the relation between the FSHR polymorphism at amino acid
position 680 (Asn/Ser) and pregnancy rate.
Jun et al. (2006) Klinkert et al. (2006)
Number of patients 263 105
Status regarding ICSI patients Not excluded Excluded
Frequency of unexplained infertility (%) 35.6 25.0
Genotype associated with signiﬁcantly higher FSH levels Ser/Ser No difference
Genotype associated with signiﬁcantly higher clinical pregnancy rate Asn/Asn Ser/Ser
ICSI, intracytoplasmic sperm injection.
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478Figure 4: Menstrual cycle-dependent serum levels of LH (A), FSH (B), estradiol (C), progesterone (D), inhibin A (E), and inhibin B (F) referenced to the day of the
LH surge (0) in women with the Asn680/Asn680 (n¼12) and the Ser680/Ser680 (n¼9) genotype from the luteo-follicular transition phase (LH -25) until ovulation
(LH þ2). Means are displayed as bars, and error bars show SEM; *P,0.05; **P,0.005.
Serum hormone concentrations during the menstrual cycle in women carrying either N
680/N
680 or S
680/S
680 allele variants of the N680S polymorphism in the FSH
receptor gene [Reproduced with permission from Greb et al. (2005), # 2005 The Endocrine Society].
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479wide studies are often carried out on more than 1000 individuals. If
the association studies have been properly designed, replication of
the results in an independent population is one of the best
methods to conﬁrm an association.
Regardless of whether a candidate gene or a genome-wide
approach is used, we suggest that in order to improve the quality
of results, genetic association studies should be carried out in
two phases: an exploratory phase, followed by a validation
phase. Whenever possible, exploratory studies should be carried
out using a genome-wide approach to maximize the chances of
identifying an association. Ideally, these exploratory studies
should be replicated, and only markers that are positive in at
least two exploratory studies should be considered for validation.
As explained previously, the identiﬁcation of an association
between a certain allele or genotype and a given disease/trait
does not necessarily mean that there is an aetiological link. Due
to the occurrence of linkage disequilibrium, in a number of
cases, the associated genetic variation will only be a marker, and
not the direct cause, of the trait; for this reason, care must be
taken when drawing conclusions from the results. The rec-
ommended second phase consists of validating the small set of
markers that were associated with the disease/trait in the explora-
tory studies. Depending on the objective, validation of the markers
can take several forms. In some cases, it may be enough to repli-
cate the association with this marker in a different study popu-
lation (e.g. if a genetic marker is predictive of response to
treatment or of disease state). On the other hand, if the aim is to
study the impact of genetic variants on molecular mechanisms,
then it will be necessary to ﬁrst either sequence or screen the
DNA region around the associated variant with a higher density
of markers in order to pinpoint the particular variation that is the
causative variation (resulting in, e.g. changes in amino acid
sequence or changes to the promoter region affecting gene
expression). Once identiﬁed, this causative variation will only be
truly validated by results of in vitro and in vivo assays, such as site-
directed mutagenesis or reporter gene assays.
On the basis of the data we have summarized, there is currently
only one polymorphism for which a sufﬁcient number of studies
have consistently identiﬁed a signiﬁcant association. Studies in
women from various ethnic backgrounds with normal ovarian
function demonstrate convincingly that SNPs in exon 10 of the
FSH receptor gene can be used as markers to predict differences
in FSHR function and ovarian response to FSH (Perez Mayorga
et al., 2000; Sudo et al., 2002; de Castro et al., 2003, 2004;
Falconer et al., 2005; Jun et al., 2006; Loutradis et al., 2006),
although ovarian response is a polygenic trait and the interaction
with other gene polymorphisms remains to be investigated.
On the contrary, no consistent association between gene
polymorphism and PCOS could be identiﬁed.
Conclusions
By pursuing the most promising polymorphisms identiﬁed in this
review, we hope that the key factors involved in the pathogenesis
of PCOS will be identiﬁed in the not-too-distant future, and that
this knowledge can be used to improve prognosis for women
with this disorder. These women are also part of a wider group
who would potentially beneﬁt from further analyses to conﬁrm
the link between variants in the FSHR gene and ovarian response
to gonadotrophins. Strong evidence for an association could ulti-
mately lead to stimulation protocols that are carefully personalized
to each woman’s individual needs, according to the particular
combination of polymorphisms inherited.
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